Results 51 to 60 of about 1,959 (184)

Pharmacogenomic tests of oncology drugs at Instituto Nacional de Câncer (INCA)

Brazilian Journal of Oncology, 2021
The implementation, current status and future perspectives of the pharmacogenetics/genomics (PGx) testing program developed at Instituto Nacional de Cancer (INCA) are presented. Initial selection of drug-gene pairs for PGx testing was based on clinically-
Guilherme Suarez-Kurtz
doaj   +1 more source

DNA-thioguanine nucleotide as a treatment marker in acute lymphoblastic leukemia patients with NUDT15 variant genotypes.

PLoS ONE, 2021
BackgroundLarge inter-individual variations in drug metabolism pose a challenge in determining 6-mercaptopurine (6MP) doses. As the last product of 6MP metabolism, DNA-thioguanine nucleotide (DNA-TGN) could reflect the efficacy of 6MP, especially in ...
Hee Young Ju, Ji Won Lee, Hee Won Cho, Ju Kyung Hyun, Youngeun Ma, Eun Sang Yi, Keon Hee Yoo, Ki Woong Sung, Rihwa Choi, Hong Hoe Koo, Soo-Youn Lee   +10 more
doaj   +1 more source

A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia [PDF]

Nature Genetics, 2014
Thiopurine therapy, commonly used in autoimmune conditions, can be complicated by life-threatening leukopenia. This leukopenia is associated with genetic variation in TPMT (encoding thiopurine S-methyltransferase). Despite a lower frequency of TPMT mutations in Asians, the incidence of thiopurine-induced leukopenia is higher in Asians than in ...
Suk-Kyun, Yang, Myunghee, Hong, Jiwon, Baek, Hyunchul, Choi, Wanting, Zhao, Yusun, Jung, Talin, Haritunians, Byong Duk, Ye, Kyung-Jo, Kim, Sang Hyoung, Park, Soo-Kyung, Park, Dong-Hoon, Yang, Marla, Dubinsky, Inchul, Lee, Dermot P B, McGovern, Jianjun, Liu, Kyuyoung, Song   +16 more
openaire   +2 more sources

Implementation of NUDT15 Genotyping to Prevent Azathioprine‐Induced Leukopenia for Patients With Autoimmune Disorders in Chinese Population [PDF]

, 2022
Azathioprine (AZA) is commonly used for many autoimmune disorders; however, the limitation of its clinical use is due to potential toxicities, including severe leukopenia.
Chung, Wen‐Hung, Po‐Wei Huang, Kao, Hsiao‐Wen, Ya‐Ching Chang, Wu, Yeong‐Jian Jan, Chang, Ya‐Ching, Chee‐Jen Chang, Wen‐Hung Chung, Wei‐Ti Chen, Chuang‐Wei Wang, Yu, Kuang‐Hui, Hsiao‐Wen Kao, Yeong‐Jian Jan Wu, Tsen‐Fang Tsai, Yu‐Jr Lin, Consortium, Taiwan Asian Severe Cutaneous Adverse Reaction, Hui, Rosaline Chung‐Yee, Lu, Chun‐Wei, Lin, Yu‐Jr, Chih‐Jung Chang, Chang, Chee‐Jen, Chun‐Wei Lu, Chen, Wei‐Ti, Chang, Chih‐Jung, Min‐Hui Chi, Chau‐Yee Ng, Hsiang‐Cheng Chen, Chen, Hsiang‐Cheng, Kuang‐Hui Yu, Rosaline Chung‐Yee Hui, Yu Huei Huang, Huang, Po‐Wei, null null, Wang, Chuang‐Wei, Chun‐Bing Chen, Chang, Yun‐Ting, Huang, Yu Huei, Chi, Min‐Hui, Tsai, Tsen‐Fang, Chen, Chun‐Bing, Ng, Chau‐Yee, Yun‐Ting Chang   +41 more
core   +1 more source

Precision medicine in paediatrics: Progress and priorities

British Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain, Claire Booth, Joseph F. Standing, Charlotte I. S. Barker   +3 more
wiley   +1 more source

Dispensing of actionable pharmacogenetic drugs among adults receiving cardiovascular disease medications in the Northern Netherlands: A serial cross‐sectional study

Clinical Pharmacology &Therapeutics, EarlyView.
The extent of pharmacogenetic (PGx) drug dispensing among Dutch adults receiving medications for cardiovascular disease (CVD) is unknown. Using the University of Groningen IADB.nl pharmacy database, we performed a serial cross‐sectional study (2019–2023) to estimate the annual prevalence of PGx drug dispensing and annual rates of initiation.
Zhuolin Zhang, Guiling Zhou, Jens H. J. Bos, Eelko Hak, Talitha Feenstra, Frank Klont   +5 more
wiley   +1 more source

Comparison of pharmacogenomic guidance in Australian prescribing resources and international pharmacogenomic guidelines

Internal Medicine Journal, EarlyView.
Abstract Background Pharmacogenomic‐guided medication management optimises drug therapy to enhance patient outcomes. Despite clinical utility, implementation in Australia remains limited, partly due to the lack of clear and consistent guidance. Aim This study evaluated the presence and consistency of pharmacogenomic testing indication categories and ...
Ruby Soueid, Jackson L. A. Thomas, Luke B. Hesson, Stephen Hughes, Sophie L. Stocker   +4 more
wiley   +1 more source

Usefulness and difficulties with the thiopurine pharmacogenomic NUDT15 genotyping test: Analysis of real-world data in Japan

Journal of Pharmacological Sciences, 2023
The usefulness of NUDT15 genotyping as a pharmacogenomic test for thiopurine has been established. The first such test developed to date, NUDT15 genotyping was approved for reimbursement in Japan in February 2019 for all indicated patients.
Yoichi Kakuta, Motohiro Kato, Yusuke Shimoyama, Takeo Naito, Rintaro Moroi, Masatake Kuroha, Hisashi Shiga, Yoshitaka Kinouchi, Atsushi Masamune   +8 more
doaj   +1 more source

Admixture Mapping Reveals Candidate Regions for Methotrexate Neurotoxicity Susceptibility: A Reducing Disparities in Acute Leukemia Consortium Report

Pediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
ABSTRACT Background Neurotoxicity is a rare, often dose‐limiting adverse effect of methotrexate (MTX) therapy that disproportionally affects Latino children. Factors contributing to the observed disparity are not well understood. This study leveraged admixture mapping to identify genetic regions associated with MTX‐related neurotoxicity susceptibility ...
Rachel D. Harris, Priya B. Shetty, Olga A. Taylor, Elizabeth G. Atkinson, Melissa A. Richard, M. Monica Gramatges, Mark Zobeck, Sandi Pruitt, Amy Hughes, M. Brooke Bernhardt, Ashley Chavana, Van Huynh, Kathleen Ludwig, Laura Klesse, Kenneth Heym, Timothy Griffin, Rodrigo Erana, Juan Carlos Bernini, Han Chen, Bing Yu, Philip J. Lupo, Karen R. Rabin, Michael E. Scheurer, Austin L. Brown, The REDIAL Consortium   +24 more
wiley   +1 more source

Operationalizing Precision Medicine in Drug Development: Predictive Biomarkers, Companion Diagnostics, and Regulatory Pathways

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 914-929, October 2026.
Precision medicine offers the opportunity to improve the benefit–risk profile of new therapies by prospectively identifying patients most likely to respond or least likely to experience harm; however, its systematic integration into drug development remains inconsistent outside oncology.
Ingrid Holst‐Laubjerg, José M.A. Moreira   +1 more
wiley   +1 more source